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Pharmacological Characterization of a Novel
Neuroactive Steroid Prodrug, NTS-104, and Its
Neuroprotective Activity in Experimental Stroke
Models
Li Zhang , MD*; Robin Schwartz-Byrne , MS*; Steven Gertz, BA; Matthew McGuire , BA; Colleen Woodhouse , BA;
Brianna Powell, BS; Min Wei, BS; Chao Li , PhD; Clare B. Billing, MS; Todd A. Verdoorn , PhD; Leslie Lam, MS;
Tom J. Parry , PhD; Benjamin Buller, PhD; Zheng Gang Zhang , MD, PhD; David Poulsen, PhD; Michael Chopp , PhD
BACKGROUND: Ischemic stroke affects about 700 000 patients per year in the United States, and to date, there are no effective
pharmacological agents that promote recovery. Here, we studied the pharmacokinetics, pharmacodynamics, and efficacy of
NTS-105, a novel neuroactive steroid, and NTS-104, a prodrug of NTS-105, in 2 models of ischemic stroke.
METHODS: The pharmacodynamics and pharmacokinetics of NTS-104/105 were investigated in naive and stroke rats, and
models of embolic and transient middle cerebral artery occlusion were used to investigate the dose-related effects of NTS104. All rats were randomly assigned into the experimental groups, and all outcome measurements were performed blindly.
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RESULTS: Blood plasma and brain pharmacokinetic analysis revealed that NTS-104 rapidly converted to NTS-105, which reached
peak concentration at ≈1 hour after dosing and distributed similarly to normal and ischemic brains. NTS-104 administration
4 hours after embolic middle cerebral artery occlusion led to a dose-dependent improvement of neurological outcomes and
a dose-dependent reduction of infarct volumes relative to vehicle-treated animals. A single dose level study confirmed that
NTS-104 administered 4 hours after transient middle cerebral artery occlusion was also neuroprotective. Quantitative ELISA
revealed that NTS-104 treatment resulted in time- and dose-dependent changes in AKT activation and cytokine levels within
the ischemic brain, which included reductions of IL-6, VEGF, ICAM-1, IL-1β, MCP-1, RAGE, and GM-CSF. Time- and dosedependent reductions in IL-6 and GM-CSF were also observed in the plasma along with an elevation of galectin-1.
CONCLUSIONS: NTS-104 is a novel prodrug that converts to a novel neuroactive steroid, NTS-105, which improves functional
outcomes in experimental ischemic stroke models.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: brain ◼ cytokine ◼ middle cerebral artery ◼ plasma ◼ prodrug

I

schemic stroke occurs in ≈700 000 patients each year
in the United States and is a leading cause of death and
disability worldwide. Approximately 5% of patients with
acute ischemic stroke receive thrombolytics or mechanical thrombectomy and of those patients, only about half
experience good outcomes as defined by a score on

the modified Rankin Scale score of 0 or 1.1,2 Thus, the
vast majority of patients with acute ischemic stroke are
in need of an effective neuroprotective/neurorestorative
therapy. Therefore, the successful pharmacological treatment of stroke remains an important clinical goal in acute
ischemic stroke.
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Nonstandard Abbreviations and Acronyms
ECA
eMCAO
GAL-1
mNSS
pAKT
tMCAO

external carotid artery
embolic middle cerebral artery occlusion
galectin 1
modified neurological severity score
phosphorylated AKT
transient middle cerebral artery occlusion
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Studies have documented the cerebroprotective
nature of neuroactive steroids and that nuclear hormone
receptors such as progesterone receptors represent valid
therapeutic targets for neuroprotection.3,4 The administration of neuroactive steroids has consistently limited
brain damage, improved functional outcomes in preclinical stroke models,5–7 and promoted multiple endogenous
recovery and restorative processes.8–11 Therefore, it is
reasonable to hypothesize that treatment with exogenous neuroactive steroids may further enhance neuroprotection and repair after a brain insult.
Here, we present the molecular structures (Figure 1A
and 1B) and pharmacokinetic and pharmacodynamic
characterization of a novel neuroactive steroid, NTS-105,
and its water-soluble pro-drug, NTS-104. These compounds were first described by the Emory Brain Research
Laboratory and the Emory Institute for Drug Development.12 The systemic and brain pharmacokinetics of the
systemically administered pro-drug NTS-104 and parent,
NTS-105 are presented herein, as are results in 2 different experimental middle cerebral artery occlusion models
(one embolic [embolic middle cerebral artery occlusion
(eMCAO)]) and the other transient middle cerebral artery
occlusion [tMCAO]), conducted in independent studies. We report that NTS-104 treatment produces robust,
dose-dependent improvements in neurological outcomes.
Further, NTS-104 treatment reduced pro-inflammatory
cytokines in the rat eMCAO stroke model and activated
AKT within the ipsilateral hemisphere. These results suggest that NTS-104 treatment may have therapeutic benefit for the treatment of acute ischemic stroke.

METHODS
Data Availability
All data collected and analyzed for this study are archived at
KCT Data (Atlanta, GA). The data that support the findings of
this study are available from the corresponding author upon
reasonable request. See the Supplemental Material for the
preclinical checklist required by the journal.

Animal Procedures
All animals in the studies presented herein were male Wistar
rats. A total of 172 rats were used in this study, of which 149
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were included in the various analyses, and 23 were excluded
due to early mortality or insufficient injury. All animal procedures
were approved by the Henry Ford Hospital Institutional Animal
Care and Use Committee under protocol number 00001003
or the University at Buffalo Institutional Animal Care and Use
Committee under protocal number NSG16037N. All studies
were conducted in compliance with the standards established
by AAALAC-International.

Measurement of NTS-104 and NTS-105 in
Plasma and Brain Samples
Male Wistar rats (N=3/group) were administered a single
intramuscular (IM) dose of NTS-104 at 10 mg/kg. Stroke
rats (see eMCAO model below) were dosed 6 hours after the
onset of ischemia. Starting at 30 minutes after initial dosing,
NTS-104 and NTS-105 concentrations in blood plasma and
brain homogenates were measured at regular intervals up to
24 hours after dosing. A qualified LC-MS/MS bioanalytical
method was used to quantify the levels of NTS-104 and NTS105 in blood plasma and brain tissue samples. The internal
standard used for NTS-104 quantitation was dexamethasone,
and the internal standard used for NTS-105 was glyburide.
These standards were chosen because they have similar
physicochemical properties to NTS-104 and -105, including
a similar molecular weight, reasonably similar structure, and
comparable solubilities, and thus were reasonable sample
handling and extraction controls.

eMCAO Model
Clot Preparation
Male Wistar rats were purchased from Charles River
Laboratories and habituated for 5 days upon arrival to laboratory
animal facility. A single, fibrin-rich white clot was prepared from
each donor rat, which were anesthetized with 3% isoflurane.
With a segment of 25 cm sterile PE-50 tubing, arterial blood
was obtained from the femoral artery. The arterial blood was
incubated for 2 hours at 37 °C, then stored overnight at 4 °C.
Before the stroke induction surgery, ≈500 mm PE-10 tubing
was connected to a 1-mL sterile saline-filled syringe. The clotcontaining PE-50 tubing was connected to the PE-10 tubing
and the clot was flushed out into the saline filled Petri dish. The
clot was then washed by repeatedly withdrawing and flushing
out 10 to 15 times with saline until it became white-pinkish in
color, signifying negligible numbers of red blood cells remained.
Clots were divided with a scalpel into 4 to 5 cm lengths and collected into a modified PE-50 catheter (end diameter 0.3–0.4
mm) connected to a 100-µL Hamilton microsyringe. All procedures were conducted under aseptic condition.

Stroke Induction
All surgery was conducted using aseptic technique and presterilized instruments. Rats were prepared for induced stroke using
the described eMCAO model.12,13 Rats (350–400 g; N=23 for
vehicle group and N=15 for all other groups) were placed in
supine position and initially anesthetized with 3.5% isoflurane
following standard aseptic procedures. Anesthesia was maintained at 2.8% isoflurane and body temperature at 37 °C during
procedure. Under a stereo microscope, a 20 to 30 mm midline
incision was made from the jaw to the clavicle and the right
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507
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Figure 1. NTS-105 enters the brain in healthy and stroke animals, while its prodrug, NTS-104 does not cross the BBB.
A, Structure of NTS-104, a neurosteroid backbone linked via an oxime to a phosphate. B, NTS-105, an oxime-containing novel neurosteroid.
Plasma concentration-time profile of NTS-104 in plasma, and NTS-105 concentration in plasma and brain after administration of a single IM
dose of 10 mg/kg NTS-104 in uninjured (C) and stroke (D) rats. NTS-104 was below the detection limit in brain at all timepoints. There are
no statistically significant differences in plasma or brain concentrations of NTS-105 between injured and uninjured animals, and there are
no statistically significant differences in any single measure from 30 to 60 min, suggesting that the true Tmax lay somewhere between these
timepoints. Data are presented as mean±SD. N=3.

common carotid artery, external carotid artery (ECA), and internal carotid artery were exposed. The right ECA was ligated with
a 4-0 silk suture and the stump of the ECA was aligned with the
common carotid artery. An aneurysm clip was placed around the
common carotid artery and internal carotid artery to temporarily induce hemostasis. A partial arteriotomy was performed on
the ECA stump and the tip of the clot filled modified PE-50
catheter was inserted into the arteriotomy. After securing the
modified PE-50 catheter at the ECA stump, the aneurysm clip
was removed, and the modified PE-50 catheter was advanced
into the internal carotid artery rostrally for 18 to 19 mm. The
clot was injected slowly in 5 to 10 µL of saline at rate of 10 µL/
minute. The modified PE-50 catheter was then removed, the
ECA stump ligated, the incision site was closed, and anesthesia
was discontinued. Afterward, rats were placed on warming pads
until recovery.

Treatment Group, Sample Size, and Dosing
Following surgery and before dosing, rats were randomized into
one of the 5 groups using a randomization scheme generated
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507

by randomizer.org: vehicle (PBS, pH 8.7), NTS-104 at doses
of 1, 3, 10, and 30 mg/kg (n=23 vehicle, and n=15/group
for treatment arms). Sample sizes were determined based on
previous unpublished pilot data. A sample size of 15 rats in
each treatment group that had baseline modified neurological
severity score (mNSS) values of 9 or greater was estimated
to have 90% power to detect a true treatment difference of
2.6 points in the change from baseline mNSS values at the
2-sided, 0.05 significance level. This estimate assumed use of
Dunnett’s procedure to adjust the significance level for the 4
active dose comparisons to vehicle control, and a SD of 1.8
points in the change from baseline of the mNSS at day 28. The
least significant difference for each comparison to vehicle was
estimated to be 1.7.
Rats were treated with IM doses of NTS-104 at rotating
sites in the hind limbs based on weight at 4, 10, 24, 48, 72,
and 96 hours after injury. The NTS-104 dosage was subsequently decreased by half at 72 hours and again at 96 hours
(see Figure 2A for experimental timeline). A nominal volume of
100 µL was used for injection, but the dose volume injected
November 2022   3
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Figure 2. NTS-104 is neuroprotective after embolic middle cerebral artery occlusion (eMCAO) and improves outcomes up to 1
mo after injury.
A, Experimental design for the embolic middle cerebral artery occlusion behavior study, including drug dosing schedule and testing days for
modified neurological severity score (mNSS), adhesive tape removal test (ATR), and foot fault (FF) assessment. B, The results of mNSS analysis,
adhesive tape removal test, and foot fault assessment. mNSS data were measured starting at day 0 for baseline inclusion criteria; all other end
points were measured starting on day 1. Data are presented as mean±SEM. N=23 for vehicle group. N=15 for treatment arms. C, A box-andwhisker plot of the distribution of infarct volumes within each treatment group; each individual’s infarct volume is also displayed. Total infarction
is in white, which the subcortical infarction is light shaded and the cortical infarction is dark shaded. Statistical significance was only found in
the total infarction measurements, but the proportion of animals having no cortical infarct increased with dose. D, Representative images of the
middle section of a single animal from each treatment group; infarcted region is outlined in black. E, Scatter plot of the mNSS on day 28 vs infarct
volume showing a highly significant correlation. *P<0.05 vs vehicle. #P<0.01 vs vehicle.

was adjusted based on the weight of each rat. Rats who died
during the first week of the experiment were replaced, and rats
who scored 8 or lower on the mNSS at 4 hours after surgery
(criteria established a priori) were excluded before randomization. Blinding codes were held by a third party who was not
involved in the conduct of the study, and all personnel involved
in the assessments were therefore blinded to treatment.

tMCAO
Stroke Induction
Male Wistar rats (N=15/group) were subjected to tMCAO. The
tMCAO surgery was conducted using the described tMCAO
model.14,15 The surgery is substantially similar to the eMCAO
model, except that the tip of a blunt-end monofilament nylon
suture was inserted into the arteriotomy and advanced 18 to
19 mm, in place of the catheter described above. After 2 hours,
4   November 2022

the rats were reanesthetized and the suture was removed to
reestablish perfusion.

Treatment Group, Sample Size, and Dosing
Following tMCAO and before dosing, rats were randomized
into one of 2 groups: vehicle or NTS-104 at 10 mg/kg administered 4 hours after tMCAO (n=15 vehicle, and n=15/group
for treatment arms). Sample sizes were determined based
on data from the eMCAO study. A sample size of 15 rats in
each treatment group that had baseline mNSS values of 9 or
greater was estimated to have 90% power to detect a true
treatment difference of 1.9 points in the change from baseline
mNSS values at the 1-sided, 0.05 significance level. This estimate assumed a SD of 1.7 points in the change from baseline
of the mNSS at day 14. The least significant difference for
the comparison to vehicle was estimated to be 1.1. Rats were
treated with IM doses of NTS-104 in the same manner as
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507
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Behavioral Analysis
Modified Neurological Severity Score
An mNSS assessment was performed on each animal within 4
hours after initiating stroke and before randomization, as previously described.13,16 Assessments were repeated 24 hours
after eMCAO injury and on days 7, 14, 21, and 28 (or days 7
and 14 for tMCAO).

Adhesive Removal Test
To evaluate sensorimotor function, an adhesive removal test
(ART) was performed at 24-hour post-injury and on days 7, 14,
21, and 28 following eMCAO (or days 7 and 14 for tMCAO) to
assess sensorimotor deficits, as we and others have previously
described.13,17

Foot Fault
To evaluate ambulation/gait, the Foot fault test was performed
at 24 hours post-injury and on days 7, 14, 21, and 28 (or days 7
and 14 for tMCAO) to assess motor recovery, as we and others
have previously described.13,18
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Infarct Volume
Twenty-eight (28) days after eMCAO, rats were euthanized and
infarct volumes were measured as follows. Rats were transcardially perfused with 0.9% saline followed by 4% paraformaldehyde. Brains were removed from the skull, fixed by incubation
in 4% paraformaldehyde at ambient temperature for several
days. Each brain was cut into 7 coronal blocks, each with 2 mm
thickness. The tissue blocks were processed and embedded,
and 6-µm-thick paraffin sections from each block were cut and
stained with hematoxylin and eosin for evaluation of infarct volume. The coronal sections were captured and digitized with the
MCID computer imaging analysis system (Imaging Research).
The area of both hemispheres and the area of infarction were
measured by digital tracing the respective areas. The infarct
volume was determined by multiplying the appropriate area
by the section interval thickness. To reduce errors associated
with tissue processing, the infarct volume is presented as the
percentage of infarct volume of the contralateral hemisphere
(indirect volume calculation).12,19

Measurement of Phosphorylated AKT, AKT, and
Cytokines
Adult, male Wistar rats (350–400 g; N=6/group) underwent
either sham surgery or eMCAO. At 6 hours after eMCAO, rats
scoring 9 or higher on the mNSS were dosed IM with a single
injection of vehicle (Tris-buffered saline, pH 8.5), or with NTS104 at 5 or 20 mg/kg in a volume of 100 µL. At 6, 12 or 24
hours after injection, rats were deeply anesthetized and exsanguinated by cardiac puncture, at which time blood samples
were collected. Rats were then perfused with 20 mL of PBS
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507

to remove blood from the cerebral vasculature. Whole blood
was collected into EDTA (K3) Monoject tubes (Covidien).
Plasma was prepared by centrifugation of whole blood for 10
minutes at 3000×g at 4 °C. Plasma samples were stored at
-80oC. After perfusion, cortical and sub-cortical brain tissue
samples from the ipsilateral hemispheres were collected on
ice in chilled PBS, snap-frozen in liquid nitrogen, and then
stored at −80 °C.
The levels of total AKT and phosphorylated AKT (pAKT)
were determined by quantitative ELISA using the RayBiotech’s
Phospho AKT (Ser473) ELISA kit (PEL-AKT-S473-Q, Atlanta,
GA) according to the manufacturer’s instructions. Cytokine
protein levels in the cortex and plasma were determined by
RayBiotech via their Quantibody Rat Cytokine Array 67. Oneway ANOVA was performed to compare groups within each
respective time point post injection.

Statistical Analysis
Assessments repeated at multiple post-treatment time points
(mNSS, foot fault, and ART) were analyzed by a linear mixedeffects model for repeated measures comparing each randomized NTS-104 treatment group to vehicle. The model included
treatment, visit, and treatment by visit interaction. The model for
mNSS also included the baseline assessment as a covariate.
The single timepoint assessment of infarct volume was analyzed using a linear ANOVA and compared each dose group
to vehicle. All statistical tests were 2-sided at the α=0.05 level
for the eMCAO study, and 1-sided at the same level for the
tMCAO study. Dunnett’s adjustment for testing multiple dose
groups versus control was used for the inferential analyses
for the eMCAO study. No additional multiplicity adjustments
(for the multiple end points and multiple analysis time points)
were performed. Analyses of the mNSS, ART, and foot fault
included data from all rats who were assigned to treatment and
who had a baseline and any post-baseline assessment. This
included rats that both completed the study and died (or were
euthanized) during the study. The distribution properties of the
data were examined, and if non-normally distributed, additional
analyses were conducted by a nonparametric method based
on ranks.

RESULTS
Pharmacokinetic in Normal and Stroke Animals

To determine the pharmacokinetic properties of NTS104 and NTS-105 under normal and neuropathologic
conditions, pharmacokinetic studies were performed in
normal and eMCAO rats. In normal rats, IM administered
NTS-104 achieved Tmax at 1 hour after IM injection in
plasma and was not measurable in plasma by 12 hours
(Table; Figure 1A). NTS-105 achieved Tmax at 1 hour after
IM injection in plasma and in brain (Table; Figure 1A).
For rats with eMCAO, NTS-104 achieved Tmax at 1 hour
after IM injection in plasma and was not measurable by
12 hours after injection (Table; Figure 1B). NTS-105
achieved Tmax at 1 hour after IM injection in plasma and
at 0.5 hour in the stroked brain (Table; Figure 1B). NTS104 was not detected in brain in any time point. These
November 2022   5
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were replaced, and rats who scored 8 or lower on the mNSS
at 4 hours after tMCAO (criteria established a priori) were
excluded before randomization. Blinding codes were held by
a third party who was not involved in the conduct of the study,
and all personnel involved in the assessments were therefore
blinded to treatment.
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Table. Pharmacokinetic Parameters of NTS-104 and NTS-105 in Plasma and Brain of Healthy and Stroke Animals After a
Single Intramuscular Injection of 10 mg/kg NTS-104
Plasma

Brain
Tmax

AUC

(ng/mL)

(nM)

(h)

(ng/mL-h)

(nM-h)

(ng/mL)

(nM)

(h)

(ng/mL-h)

(nM-h)

NTS-104

373

850

1

896

2041

NA

NA

NA

NA

NA

NTS-105

279

636

1

1214

2765

172

392

1

709

1615

NTS-104

467

1064

1

995

2267

NA

NA

NA

NA

NA

NTS-105

281

640

1

1314

2993

149

338

0.5

576

1312

Cmax

Tmax

AUC

Cmax

Healthy rats

Stroke rats

data indicate that the pharmacokinetic of NTS-104 and
NTS-105 was quite similar in normal and stroke rats.
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Efficacy of NTS-104 in eMCAO Model
In total, sixteen (16) animals died after surgery (considered related to model injuries), five (5) before, and eleven
(11) after randomization. These animals were replaced to
ensure that 15 animals completed the study from each
experimental arm. Additionally, four (4) animals were
excluded due to a nonqualifying mNSS of 8 or lower.
Before treatment, rats randomly assigned in 5 dose groups
exhibited neurological deficits based on mNSS and inclusion criteria. As expected, each treatment group had lower
average mNSS scores at each successive observation day,
indicating spontaneous partial recovery (Figure 2B). However, treatment with NTS-104 at 4 hours after eMCAO
accelerated recovery in a dose-dependent manner. While
numerical improvement was observed with all 4 doses,
only rats in the 10 and 30 mg/kg dose groups performed
significantly better compared with vehicle-treated control
animals (Figure 2B) after adjusting for Dunnett correction
for multiple comparisons. Similarly, robust improvements
in both ART and foot fault assessments were observed
over the 28 d test period with the 10 and 30 mg/kg
dose groups compared with vehicle-treated controls (Figure 2B). A significant improvement in the ART test was
also observed at day 28 in the 1 mg/kg dose group.
Rats were euthanized for infarct volume analysis
28 days after eMCAO. Average infarct volumes were
reduced in a dose-dependent fashion; however, the data
were not normally distributed based on the Shapiro-Wilk
normality test. Although Kruskal-Wallis 1-way ANOVA
on ranks revealed an overall P of 0.083, post hoc Wilcoxon rank-sum test showed that the 30 mg/kg group
had a significantly smaller average infarct volumes compared with vehicle treated controls (Figure 2C and 2D;
P<0.05). The infarct volume measurements were further broken down by cortical and subcortical location,
and while no statistically significant differences were
found, the number of animals have no apparent cortical infarction increased with dose (Figure 2C). Because
of the non-normality of the distributions, especially in
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the 10 and 30 mg/kg groups, 28-day mNSS was plotted versus infarct volume, and it was determined that
the correlation was highly linear when individual data
points were plotted (Figure 2E; R2=0.612; P<0.0001).
Notably, several animals in the 10 and 30 mg/kg group
that had large infarctions also were found to have high
28-day mNSS scores.
Efficacy of NTS-104 in tMCAO
To account for model-specific effects, especially a lack of
rapid reperfusion in the eMCAO model, a study in a second model (tMCAO) of experimental stroke model was
conducted. The lowest effective dose from the eMCAO
study (ie, 10 mg/kg) was utilized, and the observational
period was shortened from 28 to 14 days. One (1) animal
that was enrolled in this study died prematurely (not drug
related) and was replaced, and two (2) were excluded
before randomization due to nonqualifying mNSS scores.
Before drug treatment, rats in both treatment groups
performed equally on the mNSS. However, at 1 day after
injury and thereafter, NTS-104-treated animals performed
significantly better on each task than did vehicle-treated
animals (Figure 3A through 3C). Infarct volume was measured at the end of the experiment, and was similar to
the eMCAO results. The data were not normally distributed, so a nonparametric analysis was again performed.
Although the mean infarct volume was reduced in drugversus vehicle-treated animals, the effect approached but
did not achieve statistical significance based on Wilcoxon
rank-sum test (P=0.054; Figure 3D). These data indicate
that repeat dosing of 10 mg/kg NTS-104 is effective at
enhancing recovery from tMCAO.
AKT Activation and Cytokine Analysis
Quantitative ELISA was used to determine the levels of
total AKT and pAKT within the ipsilateral striatum and cortex of stroke rats with and without a single IM NTS-104
treatment of 5 or 20 mg/kg. Increases in pAKT levels were
detected in both the ischemic cortex and striatum at 6
hours after a single injection of NTS-104 (20 mg/kg) relative to vehicle. In contrast, the 5 mg/kg dose did not induce
an increase in pAKT levels relative to vehicle treated rats

Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507
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Figure 3. NTS-104 is also protective after transient middle cerebral artery occlusion (tMCAO).
Results of the behavioral outcomes of the tMCAO study for (A) modified neurological severity score (mNSS), (B) adhesive tape removal test, and
(C) foot fault assessment of rats with tMCAO surgery. mNSS mNSS data were measured starting at day 0 for baseline inclusion criteria; all other
end points were measured starting on day 1. Data are presented as mean±SEM. N=15/group. *P<0.05. Infarct volumes (D) were also measured
to be lower in drug treated rats vs vehicle control, approaching statistical significance (P=0.054).

(Figure 4A and 4B). The 20 mg/kg NTS-104 dose also
induced a decrease in pAKT levels in the striatum relative
to vehicle, but not the cortex at 12 hours after treatment. A
corresponding increase in total AKT was observed in both
the striatum and cortex at 6 hours after dosing with 20 mg/
kg of NTS-104 but not with the 5 mg/kg NTS-104 dose.
Additionally, 67 cytokines in the brain and plasma of rats
were assayed using quantitative ELISA following eMCAO.
We found that a single IM dose of NTS-104 at 20 mg/kg
significantly reduced proinflammatory cytokines interleukin-6 (IL-6), granulocyte-macrophage colony-stimulating
factor (GM-CSF)‚ monocyte chemoattractant protein-1
(MCP-1), interleukin-1β (IL-1β), receptor for advanced glycation endproducts (RAGE), vascular endothelial growth
factor (VEGF)‚ and intercellular adhesion molecule-1
within the cortex of stroked rats 6 and 12 hours after a
single IM injection (Figure 4C). The reduction in the level of
RAGE detected in the cortex extended further to 24 hours
after dosing. A time- and dose-dependent decrease in the
plasma levels of IL-6 and GM-CSF was also observed (Figure 4D). At doses of 5 or 20 mg/kg, NTS-104 increased
the circulating levels of the anti-inflammatory cytokine
Gal-1 (galectin-1) within the plasma at 6 and 12 hours
after treatment, respectively (Figure 4D).

Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507

DISCUSSION
The data presented herein suggest that NTS-104 is a
novel candidate for cerebroprotection from ischemic
stroke. NTS-104 is highly water soluble relative to similarly acting neuroactive steroids, and thus it is easier to
deliver than highly hydrophobic compounds. NTS-104,
as a phosphate prodrug of NTS-105, is rapidly dephosphorylated to NTS-105 in the plasma. Unlike NTS-104,
NTS-105 crosses the blood-brain barrier in measurable
quantities, consistent with previous reports.20 It is noteworthy that stroke did not cause a difference in the brain
concentration of NTS-105 relative to healthy animals nor
did it allow for successful penetration of NTS-104 into
the brain parenchyma. This suggests that the opening
of the blood-brain barrier is not required for NTS-105
bioavailability to the injured brain or increases brain distribution of NTS-105 following injury. Therefore, plasma
levels should be sufficient to estimate the brain exposure of NTS-105 in normal volunteers (ie, in the case
of early safety trials) and prospective stroke patients.
Although NTS-105 was measurable in brain and plasma
for the duration of the pharmacokinetic study (24 hours),
it is likely not available at therapeutic levels. Progesterone is known to be bound to plasma proteins at about
November 2022   7
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Figure 4. Several inflammation-associated proteins are altered in response to NTS-104 treatment after stroke.
AKT and pAKT were elevated in response to NTS-104 treatment (20 mg/kg) after stroke in striatum (A) and cortex (B). An ELISA-based panel
revealed many pro-inflammatory cytokines to be suppressed in cortex in repose to NTS-104 treatment, whereas the anti-inflammatory galectin-1
was unaltered in cortex (C). Two of the pro-inflammatory cytokines, IL-6 and GM-CSF were also suppressed in plasma, whereas the antiinflammatory galectin-1 was elevated in blood (D). N=6/group. Data are presented as mean±SEM. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.

98% to 99%.21 If a similar protein-binding fraction is
assumed for NTS-105, and it is also assumed that NTS105 has a similar affinity for the progesterone receptor
(~1 nmol/L), then the brain concentration of NTS-105
would fall to below efficacious levels between 5 and 10
hours after delivery, potentially requiring repeat dosing
or extended exposure over the acute poststroke period.
Importantly, the present work demonstrates that NTS104 is effective at enhancing recovery in multiple experimental ischemic stroke models. Our studies measured
both clinically relevant end points and histopathologic
changes. In each of our 2 independent stroke studies, our
prespecified primary end point was the mNSS assessment, which comprises a battery of sensorimotor tasks,
8   November 2022

under ischemic injury conditions that represent some of
the pathophysiologic changes exhibited in a large percentage of stroke patients including sensory and motor
deficits.
The present results suggest that NTS-104 is effective at reducing functional impairment in multiple
independent studies in distinct models with unique
pathophysiology. The embolic stroke model employs
the placement of a fibrin-rich clot into the origin of the
middle cerebral artery to induce stroke, which gradually restores perfusion over 24 to 48 hours.22 In contrast, the transient stroke model utilizes placement
of a suture to transiently occlude the middle cerebral
artery, in this case for 2 hours after which the suture
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507
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CONCLUSIONS
In summary, the results presented herein show that
NTS-104 delivers a potent neuroactive steroid, NTS105, which penetrates the blood-brain barrier, enhances
functional recovery after stroke in a dose-dependent/
model-independent fashion, and produces time- and
Stroke. 2022;53:00–00. DOI: 10.1161/STROKEAHA.122.038507

dose-dependent changes in circulating biomarkers that
are consistent with the putative molecular mechanisms
of action of NTS-105. Treatment with NTS-104/105
improves neurological and anatomic outcomes following experimental acute ischemic stroke in rats via multiple mechanisms, and as such, NTS-104 is undergoing
nonclinical development studies required for introduction
into normal volunteers and, subsequently, stroke patients.
These results provide strong pharmacological evidence
that NTS-104/105 could be therapeutically beneficial in
the treatment of acute ischemic stroke.
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